Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract Journal Article


Author: Bajorin, D. F.
Article Title: Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract
Abstract: This phase I trial evaluated the two-drug regimen doxorubicin and gemcitabine (AG) every other week for six cycles followed by ifosfamide, paclitaxel and cisplatin (ITP) every 3 weeks for four cycles in patients with transitional cell carcinoma of the urothelial tract. 15 patients were treated at five AG dose levels ranging up to doxorubicin 50 mg/m2 and gemcitabine 2000 mg/m2. The dose and schedule of ITP were constant at ifosfamide 1500 mg/m2 on days 1-3 and paclitaxel 200 mg/m2 and cisplatin 70 mg/m2 on day 1. Granulocyte colony-stimulating factor was self-administered between all cycles of therapy. The trial determined that AG given at alternating weeks at doses of doxorubicin 50 mg/m2 and gemcitabine 2000 mg/m2 was feasible. After completion of the AG-ITP sequence, 9 of 14 (64%) evaluable patients had a major response (3 complete responses and 6 partial responses). Phase II investigation at the highest dose level is ongoing. Copyright (C) 2000.
Keywords: clinical article; treatment outcome; clinical trial; fatigue; neutropenia; cisplatin; doxorubicin; gemcitabine; paclitaxel; methotrexate; neurotoxicity; lung toxicity; phase 2 clinical trial; anemia; nausea; thrombocytopenia; antineoplastic combined chemotherapy protocols; cyclophosphamide; dexamethasone; clinical protocol; ifosfamide; vinblastine; urothelial tract cancer; urologic neoplasms; drug response; short survey; urogenital tract tumor; phase 1 clinical trial; mesna; recombinant granulocyte colony stimulating factor; carcinoma, transitional cell; deoxycytidine; transitional cell carcinoma; clinical trials; diphenhydramine; cimetidine; humans; human; priority journal; sequenced chemotherapy
Journal Title: European Journal of Cancer
Volume: 36
Issue: Suppl. 2
ISSN: 0959-8049
Publisher: Elsevier Inc.  
Date Published: 2000-07-01
Start Page: S26
End Page: S29
Language: English
PUBMED: 10908845
PROVIDER: scopus
DOI: 10.1016/S0959-8049(00)00077-0
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Dean Bajorin
    658 Bajorin